Portopulmonary hypertension (PoPH) is a type of pulmonary vascular disease due to portal
hypertension that exhibits high morbidity and mortality. The mechanisms driving disease are …

Rationale: BMP9 (bone morphogenetic protein 9) is a circulating endothelial quiescence
factor with protective effects in pulmonary arterial hypertension (PAH). Loss-of-function …

Rationale: Hepatopulmonary syndrome (HPS) is a severe complication of liver diseases
characterized by abnormal dilation of pulmonary vessels, resulting in impaired oxygenation …

Background Studies in multiple organ systems have shown cross-talk between signaling
through the bone morphogenetic protein receptor type 2 (BMPR2) and estrogen pathways …

Bone morphogenic protein receptor 2 (BMPR2) expression and signaling are impaired in
pulmonary arterial hypertension (PAH). How BMPR2 signaling is decreased in PAH is …

Aims BMP9 and BMP10 mutations were recently identified in patients with pulmonary
arterial hypertension, but their specific roles in the pathogenesis of the disease are still …

Pulmonary arterial hypertension (PAH) is a rare and life-threatening vascular disorder,
characterised by abnormal remodelling of the pulmonary vessels and elevated pulmonary …

Rationale: Portopulmonary hypertension (PPHTN) occurs in 6% of liver transplant
candidates. The pathogenesis of this complication of portal hypertension is poorly …

Group 1 pulmonary hypertension (pulmonary arterial hypertension; PAH) is a rare disease
characterized by remodeling of the small pulmonary arteries leading to progressive …

Since its association with familial pulmonary arterial hypertension (PAH) in 2000, Bone
Morphogenetic Protein Receptor II (BMPR2) and its related signaling pathway have become …